Effects of low-dose and early versus late perindopril treatment on the progression of severe diabetic nephropathy in (mREN-2)27 rats.

It was previously reported that transgenic (mRen-2)27 rats with streptozotocin-induced diabetes mellitus progressively develop advanced nephropathy in 12 wk. These lesions are largely prevented when the angiotensin-converting enzyme inhibitor perindopril is administered from the time of induction of diabetes mellitus. This study aimed to determine the lowest dose of early perindopril treatment required for substantial improvement of renal function and structure and to investigate whether late intervention prevents or reverses the progression of established renal lesions. At 6 wk of age, female heterozygous Ren-2 rats were randomized to receive either streptozotocin (diabetic) or citrate buffer (control). Rats were gavaged, beginning early after the induction of diabetes mellitus or the administration of control vehicle, with 0, 0.02, 0.2, or 2 mg/kg per d perindopril for 12 wk. A separate group of diabetic Ren-2 rats received late treatment with 2 mg/kg per d perindopril throughout week 8 to week 12, when rats were hypertensive and albuminuric and exhibited increased kidney weight and glomerulosclerotic index (GSI). Among diabetic rats, early 0.02 mg/kg per d perindopril treatment reduced systolic BP, GSI, and renal collagen staining but had no effect on albuminuria or kidney hypertrophy. Early 0.2 or 2 mg/kg per d perindopril treatment further reduced systolic BP, GSI, and renal collagen staining and decreased albuminuria and kidney hypertrophy. Late intervention was as antihypertensive and antialbuminuric as early 0.2 or 2 mg/kg per d perindopril treatment but did not prevent a moderate increase in GSI. In conclusion, early treatment with 0.2 mg/kg per d perindopril was the lowest dosage to largely prevent severe diabetic nephropathy in transgenic Ren-2 rats. Late-onset perindopril treatment of diabetic rats with established nephropathy was as efficacious as early treatment with respect to various renal parameters, such as albuminuria, but was associated with moderate progression of glomerulosclerosis.

[1]  H. Holthöfer,et al.  Hypercholesterolemia is a prerequisite for puromycin inducible damage in mouse kidney. , 2003, Kidney international.

[2]  M. Cooper,et al.  Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  C. Mogensen The kidney in diabetes: how to control renal and related cardiovascular complications. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[4]  M. Cooper,et al.  Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study , 2000, BMJ : British Medical Journal.

[5]  M. Cooper,et al.  Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat. , 2000, Kidney international.

[6]  H. Koomans,et al.  ACE inhibition delays development of terminal renal failure in the presence of severe albuminuria. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  G. Remuzzi,et al.  The role of protein traffic in the progression of renal diseases. , 2000, Annual review of medicine.

[8]  B. Fabris,et al.  Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats. , 1999, Journal of hypertension.

[9]  R. Bain,et al.  Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  N. Perico,et al.  ACE inhibition induces regression of proteinuria and halts progression of renal damage in a genetic model of progressive nephropathy. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  C. Johnston,et al.  Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy. Implications for the pathogenesis of tubulointerstitial fibrosis. , 1999, The American journal of pathology.

[12]  M. Cooper,et al.  Increased bradykinin and "normal" angiotensin peptide levels in diabetic Sprague-Dawley and transgenic (mRen-2)27 rats. , 1999, Kidney international.

[13]  M. Mulvany Effects of angiotensin-converting enzyme inhibition on vascular remodeling of resistance vessels in hypertensive patients. , 1998, Metabolism: clinical and experimental.

[14]  F. Martin,et al.  Effects of perindopril on renal histomorphometry in diabetic subjects with microalbuminuria: a 3-year placebo-controlled biopsy study. , 1998, Metabolism: clinical and experimental.

[15]  R. Ferrari Effect of ACE inhibition on myocardial ischaemia. , 1998, European heart journal.

[16]  M. Cooper,et al.  A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). , 1998, Kidney international.

[17]  J. Mullins,et al.  Inhibition of tissue angiotensin converting enzyme activity prevents malignant hypertension in TGR(mREN2)27 , 1998, Journal of hypertension.

[18]  S. Anderson Role of local and systemic angiotensin in diabetic renal disease. , 1997, Kidney international. Supplement.

[19]  C. Tsalamandris,et al.  Why is proteinuria such an important risk factor for progression in clinical trials? , 1997, Kidney international. Supplement.

[20]  O. E. Michaelis,et al.  Perindopril ameliorates glomerular and renal tubulointerstitial injury in the SHR/N-corpulent rat. , 1997, Hypertension.

[21]  M. Cooper,et al.  Role of Angiotensin II and Bradykinin in Experimental Diabetic Nephropathy: Functional and Structural Studies , 1997, Diabetes.

[22]  W. Fierlbeck,et al.  Effects of early and late antihypertensive treatment on extracellular matrix proteins and mononuclear cells in uninephrectomized SHR. , 1997, Kidney international.

[23]  M. Myers A dose-response study of perindopril in hypertension: effects on blood pressure 6 and 24 h after dosing. Perindopril Multicentre Dose-Response Study Group. , 1996, The Canadian journal of cardiology.

[24]  J. Campbell,et al.  Short-term and long-term cardiovascular actions of different doses of perindopril in the rabbit. , 1996, Pharmacological research.

[25]  K. Duggan,et al.  DIFFERENTIAL EFFICACY OF PERINDOPRIL AND ENALAPRIL IN EXPERIMENTAL DIABETIC NEPHROPATHY , 1996, Clinical and experimental pharmacology & physiology.

[26]  G. Remuzzi,et al.  Abnormal permeability to proteins and glomerular lesions: a meta-analysis of experimental and human studies. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27]  D. Sutherland,et al.  Sequential renal biopsies in insulin-dependent diabetic patients: structural factors associated with clinical progression. , 1995, Kidney international.

[28]  T. Unger,et al.  Chronic low-dose treatment with perindopril improves cardiac function in stroke-prone spontaneously hypertensive rats by potentiation of endogenous bradykinin. , 1995, The American journal of cardiology.

[29]  D. Ganten,et al.  Angiotensin II receptor blockade in TGR(mREN2)27: effects of renin–angiotensin-system gene expression and cardiovascular functions , 1995, Journal of hypertension.

[30]  D. Heudes,et al.  Morphometric detection of incipient glomerular lesions in diabetic nephropathy in rats. Protective effects of ACE inhibition. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[31]  M. Cooper,et al.  Comparison of effects of ACE inhibition with calcium channel blockade on renal disease in a model combining genetic hypertension and diabetes. , 1995, American journal of hypertension.

[32]  I. Antony,et al.  Clinical review of perindopril in the treatment of hypertension. , 1994, The Canadian journal of cardiology.

[33]  G. Bakris,et al.  Microalbuminuria and progressive renal disease. , 1994, Journal of human hypertension.

[34]  N. Perico,et al.  Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started. , 1994, Journal of the American Society of Nephrology : JASN.

[35]  S. Anderson,et al.  Glomerular adaptations with normal aging and with long-term converting enzyme inhibition in rats. , 1994, The American journal of physiology.

[36]  A Fournier,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1994, The New England journal of medicine.

[37]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[38]  J. Ingelfinger,et al.  Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. , 1993, The American journal of physiology.

[39]  G. Jerums,et al.  The Effects of Perindopril and Triple Therapy in a Normotensive Model of Diabetic Nephropathy , 1993, Diabetes.

[40]  G. Jerums,et al.  Antihypertensive therapy in a model combining spontaneous hypertension with diabetes. , 1992, Kidney international.

[41]  A. Fogo,et al.  Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. , 1991, Kidney international.

[42]  G. Viberti,et al.  Risk factors for renal and cardiovascular disease in diabetic patients. , 1991, The Cardiology.

[43]  J. Reid,et al.  Perindopril. A review of its pharmacokinetics and clinical pharmacology. , 1990, Drugs.

[44]  B. Brenner,et al.  Short and long term effects of antihypertensive therapy in the diabetic rat. , 1989, Kidney international.

[45]  G. Jerums,et al.  Genetic hypertension accelerates nephropathy in the streptozotocin diabetic rat. , 1988, American journal of hypertension.

[46]  B. Brenner,et al.  Reversing glomerular hypertension stabilizes established glomerular injury in renal ablation. , 1986, Journal of Hypertension - Supplement.

[47]  R. Buñag Validation in awake rats of a tail-cuff method for measuring systolic pressure. , 1973, Journal of applied physiology.